Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234064 | 0.89 | DPP4 (0.38) | MMEL1SMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL16310216 | 0.85 | DPP4 (0.40) | MMEL1SMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL13084117 | 0.84 | DPP4 (0.37) | SMN1; SMN2RAB9AHPGDNPC1L3MBTL1 | |
| SCHEMBL3705644 | 0.83 | DPP4 (0.44) | MMEL1DPP4PIN1 | |
| SCHEMBL4751469 | 0.83 | DPP4 (0.38) | MMEL1DPP4ITGB3 | |
| SCHEMBL19510004 | 0.81 | DPP4 (0.40) | MMEL1DPP4CTSKITGB3ITGA2B | |
| SCHEMBL699084 | 0.80 | DPP4 (0.39) | MMEL1DPP4PIN1 | |
| SCHEMBL699083 | 0.80 | DPP4 (0.39) | MMEL1DPP4PIN1 | |
| SCHEMBL342707 | 0.79 | DPP4 (0.43) | DPP4CTSKPIN1 | |
| SCHEMBL342708 | 0.79 | DPP4 (0.43) | DPP4CTSKPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912327-B2 | Process for the production of sitagliptin | CHEMO IBERICA, S.A. (ES) | 2014-12-16 | — | — | US | disclosed |
| US-20140081026-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | CHEMO IBERICA S.A. (ES) | 2014-03-20 | — | — | US | disclosed |
| WO-2012150328-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | CHEMO IBERICA, S.A. (ES) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081026-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | DPP4, DPP7, DPP3 | MMEL1 1201/4885SMN1; SMN2 3354/4885RAB9A 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.